Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03461432
Other study ID # 231245
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 31, 2018
Est. completion date December 31, 2019

Study information

Verified date February 2018
Source King's College London
Contact Benedetta Seccomandi, PhD student
Phone 02078485728
Email benedetta.seccomandi@kcl.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cognitive deficits have been shown to have negative impact on social functioning and functional goals such as ability to work and perform daily tasks in people with schizophrenia. There is evidence that Cognitive Remediation Therapy, a form of psychological therapy, is effective in improving cognition and functioning but there is still a limited understanding of what influence people's different response to this therapy. A tailored treatment is likely to be more effective because it will adapt to service users' unique characteristics.

The investigators are planning a study exploring at the feasibility and acceptability of novel form of Cognitive Remediation Therapy which is personalised (pCRT) to the person individual characteristics. The personalised therapy will consist of task practice using computerized Cognitive Remediation software (i.e. called CIRCuiTS). The knowledge gathered in this work will contribute to develop the next generation of personalised treatment approaches for people with schizophrenia.


Description:

Cognitive deficits in people with psychosis have been shown to have negative impact on functional goals including the ability to work and perform daily tasks. Cognitive Remediation Therapy (CRT) is a psychological therapy developed to improve cognitive functions in people with schizophrenia but ultimately with a focus on improving social and functional outcomes. There is evidence that CRT is effective in improving cognition and functioning but there is still a limited understanding of the mechanisms responsible for different treatment responses. This study attempts to fill this gap by developing and testing a new form of CRT, which will personalise therapy elements according to participants' characteristics. The therapy will consist of task practice using a computerised Cognitive Remediation software and supervised activities supported by a therapist to boost functioning. The knowledge gathered in this work will contribute to develop the next generation of personalised treatment approaches for people with schizophrenia.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 15
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- a range of 18-65 years

- English speaking or with a good knowledge of the language

- a diagnosis of schizophrenia or schizoaffective disorder according to the DSM- V

- at least one year contact with mental health services,

- a deficit (of at least one standard deviation below the mean) in at least one cognitive domain out of these three cognitive domains: memory, executive function and information processing.

Exclusion Criteria:

- Planned medication change

- Diagnosis of learning disability

- Presence of cognitive deficits related to organic causes or head injury

- Primary diagnosis of substance dependence

Study Design


Intervention

Behavioral:
Cognitive Remediation Therapy
Cognitive Remediation Therapy (CRT) is a psychological therapy that has been developed with a general immediate focus on improving impaired cognitive domains but ultimately aimed at improving social and functional outcomes.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
King's College London

References & Publications (1)

Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011 May;168(5):472-85. doi: 10.1176/appi.ajp.2010.10060855. Epub 2011 Mar 15. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of intervention (including acceptance rates, drop outs) Feasibility estimates of delivering the intervention including acceptance rates, drop outs. 3 months post baseline assessment
Secondary Acceptability of intervention (Satisfaction) Questionnaire of Satisfaction 3 months post baseline assessment
See also
  Status Clinical Trial Phase
Recruiting NCT05414058 - Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Functional and Cognitive Outcomes Phase 2
Recruiting NCT05660018 - TMS Related Biomarker Assessments N/A
Not yet recruiting NCT06275451 - Qualitative Study of Emotional Regulation in Schizophrenia
Active, not recruiting NCT04325386 - Clozapine CHAMPION-ECHO Educational Study to Improve Clozapine Use. N/A
Completed NCT04567524 - A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules Phase 2
Recruiting NCT05643196 - Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia Phase 2